Rigontec GmbH, which is developing RNA-based immunotherapeutics for cancer and viral diseases, has completed a €29.25 million series A funding with a final €15 million tranche issued to its venture capital shareholders. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
